NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Genetic Technologies Limited (AU: GTG)

 
GTG Technical Analysis
1
As on 16th Oct 2024 GTG STOCK Price closed @ 0.04 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

GTGSTOCK Price

Open 0.04 Change Price %
High 0.04 1 Day N/A N/A
Low 0.04 1 Week 0.00 0.00
Close 0.04 1 Month 0.00 0.00
Volume 10071 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
AU Australia Most Active Stocks
SYA 0.04 %
PLS 2.69 %
MKG 0.02 %
RDN 0.03 %
A1G 0.11 %
AZY 0.03 %
MMI 0.05 %
HWK 0.09 %
ERA 0.01 %
PEC 0.02 %
 
AU Australia Top Gainers Stocks
APV 0.02 100.00%
SCI 0.03 50.00%
SCI 0.03 50.00%
SCI 0.03 50.00%
SCI 0.03 50.00%
SCI 0.03 50.00%
SCI 0.03 50.00%
TIN 0.74 17.46%
FNP 0.38 11.76%
RBL 0.42 10.53%
 
AU Australia Top Losers Stocks
RCP 0.02 -33.33%
RCP 0.02 -33.33%
BEM 0.06 -14.29%
BEM 0.06 -14.29%
BEM 0.06 -14.29%
BEM 0.06 -14.29%
BEM 0.06 -14.29%
BEM 0.06 -14.29%
TRL 0.07 -12.50%
TRL 0.07 -12.50%
 
 
GTG
Daily Charts
GTG
Intraday Charts
Whats New @
Bazaartrend
GTG
Free Analysis
 
GTG Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
GTG Forecast October 2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
GTG Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
GTG Forecast2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
GTG Other Details
Segment EQ
Market Capital 55356544.00
Sector Healthcare
Industry Diagnostics & Research
Offical website >
 
GTG Address
GTG
 
GTG Latest News
 
Your Comments and Response on Genetic Technologies Limited
 
GTG Business Profile
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia. Address: 60-66 Hanover Street, Fitzroy, VIC, Australia, 3065
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service